Dyadic International, Inc. (DYAI)
NASDAQ: DYAI · Real-Time Price · USD
1.060
-0.040 (-3.64%)
At close: May 13, 2025, 4:00 PM
1.120
+0.060 (5.66%)
Pre-market: May 14, 2025, 7:00 AM EDT
Dyadic International Revenue
In the year 2024, Dyadic International had annual revenue of $3.50M with 20.58% growth. Dyadic International had revenue of $817.38K in the quarter ending December 31, 2024, with 19.06% growth.
Revenue (ttm)
$3.50M
Revenue Growth
+20.58%
P/S Ratio
8.89
Revenue / Employee
$582,565
Employees
6
Market Cap
31.90M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 3.50M | 596.58K | 20.58% |
| Dec 31, 2023 | 2.90M | -31.50K | -1.07% |
| Dec 31, 2022 | 2.93M | 526.47K | 21.90% |
| Dec 31, 2021 | 2.40M | 801.91K | 50.06% |
| Dec 31, 2020 | 1.60M | -79.16K | -4.71% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
DYAI News
- 12 days ago - Dyadic to Report First Quarter 2025 Financial Results on Wednesday, May 14, 2025 - GlobeNewsWire
- 27 days ago - Dyadic to Present at World Vaccine Congress | Washington - GlobeNewsWire
- 6 weeks ago - Dyadic International, Inc. (DYAI) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Dyadic Reports 2024 Year-End Financial Results and Business Updates - GlobeNewsWire
- 2 months ago - Dyadic to Report 2024 Full Year Financial Results and Host Conference call on Wednesday, March 26, 2025 - GlobeNewsWire
- 2 months ago - Dyadic to Attend Multiple Industry Events in March - GlobeNewsWire
- 4 months ago - Dyadic Provides Business Update; Dyadic to Attend the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 6 months ago - Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology - GlobeNewsWire